Stock comparison
Haemonetics
PTC Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
PTCT
PTC Therapeutics
Market cap
$5.71B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | PTCT | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 57D | HAE |
| Benjamin Graham | 85A | 35D | HAE |
| Philip Fisher | 60C | 63C | PTCT |
| Peter Lynch | 54C | 62C | PTCT |
| Joel Greenblatt | 31F | 4F | HAE |
| Charlie Munger | 54D | 55D | PTCT |
| Terry Smith | 55D | 57C | PTCT |
Side-by-side metrics
| Metric | HAE | PTCT |
|---|---|---|
| Market cap | $2.98B | $5.71B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | 6.2x |
| ROIC (TTM) | 8.37% | -2.38% |
| Gross margin | 55.74% | 77.84% |
| Net margin | 7.29% | -22.58% |
| Revenue CAGR 5y | 7.65% | 33.89% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Net margin7.29%vs -22.58%+132%
- ROIC (TTM)8.37%vs -2.38%+128%
PTCT leads on
- P/E (TTM)-vs 24.8x+181%
- Debt / Equity-vs 1.5x+170%
- Revenue CAGR 5y33.89%vs 7.65%+77%
- EV/EBIT6.2xvs 14.1x+56%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.